Verapamil kinetics in normal subjects and patients with coronary artery spasm.
about
Prolonged half-life of verapamil in a case of overdose: implications for therapy.Pharmacokinetics and pharmacodynamics of two formulations of verapamil.The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectorisAn investigation of the cause of accumulation of verapamil during regular dosing in patients.Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells.New Verapamil Analogs Inhibit Intracellular Mycobacteria without Affecting the Functions of Mycobacterium-Specific T Cells.Effects of calcium channel blockers on potassium homeostasis.Calcium antagonists, a new class of antihypertensive agents.Controlled-release formulations of propranolol and verapamil.Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics.A nonlinear physiologic pharmacokinetic model: I. Steady-state.Pharmacokinetics of conventional and slow-release verapamil.Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.The effect of oral verapamil therapy on antipyrine clearance.Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administrationEffects of acute and chronic sunitinib treatment on cardiac function and calcium/calmodulin-dependent protein kinase II.R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.Verapamil pharmacokinetics and apparent hepatic and renal blood flow.The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.Race but not age affects erythromycin breath test results in older hypertensive men.Differences in oral verapamil absorption as a function of time of day.Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.Verapamil pharmacokinetics.Verapamil-rifampin interaction.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
P2860
Q34347331-ED056DF8-5BBD-40DB-B896-44C8F08F7CBAQ34417142-270479F5-2158-4E7F-898C-1CD078FBB463Q34417220-EFC106FB-C0C9-4696-A981-1A9193C4CD82Q34622637-2AF3D23E-3847-421B-BD5D-945E9ED1D8C0Q35886788-185A8C6C-0CC7-4F10-86F6-AE3359F5A0E5Q36644842-5B263C03-3257-44EB-B55A-AF564F508BD3Q36821699-ECCBC2A2-4F1F-48DE-A19B-C3D9B74D59A0Q39651572-FA2BCB07-78BC-4642-83B0-5A99FD29D31BQ39679813-80E2842B-63FD-417A-8C98-05C31CA615FBQ40253273-37A46A98-01BE-4AE5-977B-22B7061EB356Q41391428-9631B968-FC57-44AD-9AB6-F34034497270Q41821629-73D1DA16-C6CC-49B3-AB48-626F7733EF0AQ42126042-E8E9A48E-5CAD-4D87-83B4-F3328E73A524Q42231825-721A4EF0-5038-4A74-8580-158D9662522EQ42532060-EEBB08E3-CE8D-4F1A-93CC-0ACB9271E410Q43019107-565B1B08-042C-4A39-9BDB-5DCAA765C7DDQ43201462-87BB439C-F492-4E73-A681-78F2E02B322FQ43222574-CEEA507D-8A63-4F98-85CF-0F9F7A8EF948Q43240156-2329B963-7271-493B-9B40-FC7A206E0FA8Q43240431-DEF3A813-A8FE-4B4C-B254-886815922251Q43554159-D944C7E0-8F2E-4B6F-9153-1467F11F9FCBQ44009183-25E3D5CD-039A-49AC-B571-0DBF420E687BQ46511734-F5F8F76F-A6BD-40B9-9997-0E19E0ED3797Q46530481-A816ADD8-A234-44D1-B249-DFCFEB737FC0Q49311589-84E04B51-260A-4FA7-AB23-82AD14F7B2C9Q52334679-D1045F62-ECF0-465A-9237-398DB208C89D
P2860
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年学术文章
@wuu
1981年学术文章
@zh
1981年学术文章
@zh-cn
1981年学术文章
@zh-hans
1981年学术文章
@zh-my
1981年学术文章
@zh-sg
1981年學術文章
@yue
1981年學術文章
@zh-hant
name
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@en
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@nl
type
label
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@en
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@nl
prefLabel
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@en
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@nl
P2093
P356
P1476
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
@en
P2093
Freedman SB
Richmond DR
P304
P356
10.1038/CLPT.1981.216
P407
P577
1981-11-01T00:00:00Z